Cue Biopharma, Inc. (CUE) Reaches $14.22 After 8.00% Up Move; Id Systems (IDSY)’s Sentiment Is 1.08

June 8, 2018 - By Marie Mckinney

I.D. Systems, Inc. (NASDAQ:IDSY) Logo

Id Systems Inc (IDSY) investors sentiment increased to 1.08 in Q1 2018. It’s up 0.61, from 0.47 in 2017Q4. The ratio has increased, as 13 investment professionals started new or increased stock positions, while 12 sold and decreased equity positions in Id Systems Inc. The investment professionals in our database now have: 5.79 million shares, up from 5.65 million shares in 2017Q4. Also, the number of investment professionals holding Id Systems Inc in top ten stock positions increased from 0 to 1 for an increase of 1. Sold All: 0 Reduced: 12 Increased: 9 New Position: 4.

The stock of Cue Biopharma, Inc. (NASDAQ:CUE) is a huge mover today! The stock increased 4.18% or $0.57 during the last trading session, reaching $14.22. About 63,684 shares traded. Cue Biopharma, Inc. (NASDAQ:CUE) has 0.00% since June 8, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical CUE News: ; 12/03/2018 – MEDIA-Apple’s Eddy Cue explains Co’s original video content strategy- TechCrunch; 02/05/2018 – Cue™ Vapor System (Cue) Teams with Country Music Star Granger Smith to Bring Fans VIP Concert Experience; 10/05/2018 – Cue Biopharma to Host Investor Business Update Call and Webcast; 12/03/2018 – CNET Taiwan: Apple’s Eddy Cue talks Texture buy and `trusted news sources’; 05/05/2018 – DJ Cue Biopharma Inc, Inst Holders, 1Q 2018 (CUE); 12/03/2018 – Apple’s Eddy Cue said a Netflix or Disney acquisition is unlikely; 12/03/2018 – CORRECT: APPLE’S CUE SUGGESTS CO. WON’T BUY NETFLIX; 04/05/2018 – Apple’s Eddy Cue to Be Deposed in Qualcomm Patent Battle; 04/05/2018 – Qualcomm to depose Apple services chief Eddy Cue; 20/03/2018 – KKR Launches China’s First One-Stop Digital Marketing Company Cue & CoThe move comes after 6 months positive chart setup for the $286.26M company. It was reported on Jun, 8 by We have $15.36 PT which if reached, will make NASDAQ:CUE worth $22.90 million more.

More news for Cue Biopharma, Inc. (NASDAQ:CUE) were recently published by:, which released: “Cue Biopharma to Host Investor Business Update Call and Webcast” on May 10, 2018.‘s article titled: “The Top 5 New Buys of First Eagle Investment” and published on May 30, 2018 is yet another important article.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. The company has market cap of $286.26 million. The Company’s lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. It currently has negative earnings. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells.

Another recent and important I.D. Systems, Inc. (NASDAQ:IDSY) news was published by which published an article titled: “ID Systems Sets May 2018 Financial Conference Schedule” on May 18, 2018.

Analysts await I.D. Systems, Inc. (NASDAQ:IDSY) to report earnings on August, 2. They expect $-0.01 earnings per share, up 83.33% or $0.05 from last year’s $-0.06 per share. After $-0.06 actual earnings per share reported by I.D. Systems, Inc. for the previous quarter, Wall Street now forecasts -83.33% EPS growth.

Since January 1, 0001, it had 2 insider buys, and 2 sales for $49,395 activity.

Cannell Capital Llc holds 3.41% of its portfolio in I.D. Systems, Inc. for 1.70 million shares. Archon Capital Management Llc owns 643,255 shares or 0.4% of their US portfolio. Moreover, Bard Associates Inc has 0.39% invested in the company for 124,305 shares. The Connecticut-based Ardsley Advisory Partners has invested 0.36% in the stock. Punch & Associates Investment Management Inc., a Minnesota-based fund reported 366,546 shares.

I.D. Systems, Inc. (NASDAQ:IDSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: